Alimera Sciences Shares Outstanding 2009-2021 | ALIM

Alimera Sciences shares outstanding from 2009 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Alimera Sciences Annual Shares Outstanding
(Millions of Shares)
2020 5
2019 5
2018 6
2017 4
2016 4
2015 3
2014 3
2013 2
2012 2
2011 2
2010 1
2009 0
2008 0
Alimera Sciences Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 7
2021-03-31 6
2020-12-31 5
2020-09-30 5
2020-06-30 5
2020-03-31 5
2019-12-31 5
2019-09-30 5
2019-06-30 5
2019-03-31 5
2018-12-31 6
2018-09-30 5
2018-06-30 5
2018-03-31 5
2017-12-31 4
2017-09-30 5
2017-06-30 4
2017-03-31 4
2016-12-31 4
2016-09-30 4
2016-06-30 3
2016-03-31 3
2015-12-31 3
2015-09-30 3
2015-06-30 3
2015-03-31 3
2014-12-31 3
2014-09-30 3
2014-06-30 3
2014-03-31 2
2013-12-31 2
2013-09-30 2
2013-06-30 2
2013-03-31 2
2012-12-31 2
2012-09-30 2
2012-06-30 2
2012-03-31 2
2011-12-31 2
2011-09-30 2
2011-06-30 2
2011-03-31 2
2010-12-31 1
2010-09-30 2
2010-06-30 2
2010-03-31 0
2009-12-31 0
2009-09-30 0
2009-06-30 0
2009-03-31 0
2008-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.033B $0.051B
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29